What Do Analysts Think About GeneDx Holdings Corp. (WGS)?

Core Insights - GeneDx Holdings Corp. (NASDAQ:WGS) is recognized as one of the 12 best genomics stocks to invest in [1] Analyst Ratings - Canaccord raised its price target for GeneDx from $160 to $170, maintaining a Buy rating, citing strong industry momentum expected to continue into 2026 [2] - Wells Fargo increased its target price for GeneDx from $140 to $155, rating the stock as Equal Weight, highlighting potential improvements due to clearer U.S. pharmaceutical policies and solid growth projections [3] Financial Projections - The company has increased its revenue projection for 2025 to between $425 million and $428 million, indicating a focus on high-profitable growth [4] - GeneDx aims to leverage genomic and clinical data to enhance precision medicine, positioning itself uniquely in the healthcare market [4]